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Investigations on prostate inﬂammation-related disorders, including acute and chronic prostatitis, chronic pelvic pain syndrome,
benign prostate hyperplasia (BPH), and prostate cancer (PCa), are still ongoing to ﬁnd new, accurate, and noninvasive biomarkers
for a diﬀerential diagnosis of those pathological conditions sharing some common macroscopic features. Moreover, an ideal
biomarker should be useful for risk assessment of prostate inﬂammation progression to more severe disorders, like BPH or PCa,
as well as for monitoring of treatment response and prognosis establishment in carcinoma cases. Recent literature evidence
highlighted that changes in the expression of transglutaminases, enzymes that catalyze transamidation reactions leading to
posttranslational modiﬁcations of soluble proteins, occur in prostate inﬂammation-related disorders. This review focuses on the
role speciﬁcally played by transglutaminases 4 (TG4) and 2 (TG2) and suggests that both isoenzymes hold a potential to be
included in the list of candidates as novel diagnostic biomarkers for the above-cited prostate pathological conditions.
1. Introduction
Prostate is classiﬁed as an immune-competent organ, being
populated by leukocytes, including stromal and intraepithelial
T and B lymphocytes, macrophages, and mast cells; notably,
the number of leukocytes increases with aging [1]. In retro-
spect, it is signiﬁcant to note that reviews of immunobiological
studies of the prostate and patients with diseases thereof (the
latest of which is [2]), including observations and suggestion
of the existence of a local immunological system, i.e., “prostate
lymphoreticular system,” ergo “being classiﬁed as an immune-
competent organ” [1],weremade prior tomore contemporary
observations. In the last decades, clinical trials and epidemio-
logical observations have shown that prostate inﬂammation is
a common condition in aged men [3–5].
Prostate inﬂammation is classiﬁed through histological
evaluation of the amount of inﬂammatory cells and their
eﬀect on prostate tissue [6]. The prostate inﬂammatory pro-
cess may be triggered through diﬀerent molecular pathways
of the immune system, which are dysregulated secondarily
to diﬀerent factors: infectious bacterial agents, viruses, or
other sexually transmitted microorganisms, urinary reﬂux,
aging, dietary factors, hormones, autoimmune response, or
a combination of these factors [1, 2, 7, 8].
Inﬂammation is typically distinguished as acute (neutro-
philic cell inﬁltrate) and chronic (mononuclear cell inﬁltrate)
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[9]. Prostate inﬂammation may become a chronic process
when the microorganism causing acute prostatitis is not
eradicated.
Chronic prostatitis (CP) is a clinical syndrome, aﬀecting
10% of the male elderly population, characterized by lower
genitourinary tract and/or genital pain or discomfort and
by inﬂammatory cells in prostatic secretions [10]. It has also
been deﬁned as CP/chronic pelvic pain syndrome (CP/CPPS)
since it is not always caused by an infection. The presence of
mononuclear inﬂammatory cells in the prostate is not diag-
nostic for CP/CPPS, and other inﬂammatory cells, such as
T-cells, are commonly detected [4].
Chronic inﬂammatory processes are accompanied by the
release of large amounts of proinﬂammatory cytokines, as
well as oxygen and nitrogen reactive species (ROS and
RNS). Oxidative stress plays a key role in the pathogenesis
of CP/CPPS [11]. Cell response to both inﬂammation and
oxidative stress involves the activation of transcription factor
nuclear factor-kappa B (NF-κB), leading to the upregulation
of genes encoding for proinﬂammatory cytokines, the levels
of which are further increased, as well as chemotactic factors
and growth factors [12]. Several evidences show the presence
of oxidative stress markers in the secretions of the genitouri-
nary tract in patients aﬀected by prostate inﬂammation [11].
Notably, chronic prostate inﬂammation is a process that
could lead to the development of more severe prostatic disor-
ders, like benign prostatic hyperplasia and prostate cancer,
and also of the genitourinary tract [1, 2, 13–17].
Benign prostatic hyperplasia (BPH), the most common
urological disorder in 70-80-year-old men [18], is a chronic
progressive condition due to a nonmalignant propagation
of stromal and epithelial cells eventually leading to prostate
enlargement, associated with the development of nodules
and proliferative inﬂammatory atrophy [19]. The pathogene-
sis and progression mechanisms of BPH are still not well
characterized, but they likely involve several factors, i.e.,
changes in epithelial-stromal interactions, alterations of local
endocrine and autonomous nerve system, tissue damage, and
subsequent chronic tissue healing. Some authors have assim-
ilated BPH to an immune-mediated inﬂammatory disease
[13, 14, 20–22], others suggested a relationship between pros-
tatic inﬂammation and lower urinary tract symptoms
(LUTS) [3, 4] and/or other promotional factors common to
BPH and PCa [14].
Prostate cancer (PCa) is considered as a chronic disease
and the most prevalent cancer in the male population [23].
Epidemiological studies suggest that PCa is hormone-
dependent and is associated with inﬂammation, as sug-
gested by the detection of PCa susceptibility genes involved,
such as RNAseL, MSR1, TLR4, MIC1, PON1, BRCA2,
CHEK2, and OGG, which have a role in prostate carcino-
genesis, and also in the host response to infection, inﬂam-
mation, and oxidative stress [24, 25]. However, there is
not a clear evidence showing that a reduction of PCa inci-
dence and progression may be achieved through inhibition
of prostate inﬂammation [26].
In the last years, great eﬀorts have been undertaken to
identify novel biomarkers that, alone or combined with the
calculation of risks for the progression of prostate inﬂamma-
tion to BPH or PCa, may reduce the need for unnecessary
biopsies, improve the stratiﬁcation of low-risk patients,
and better predict the response to treatments. Moreover,
ideal biomarkers should also be able to accurately discrim-
inate between indolent and aggressive cancers and identify
men at high risk for developing PCa that require immedi-
ate treatment [27].
Several lines of evidence suggest that a key role in inﬂam-
matory processes and in the inﬂammation-induced progres-
sion of several types of cancers is played by transglutaminase
2 (TG2) or tissue transglutaminase. TG2 is an ubiquitous
member of the transglutaminase (TG) family of enzymes,
that catalyze calcium-dependent transamidation reactions
through the incorporation of amines to glutamine residues
(polyamination) or cross-linking of lysine residues to gluta-
mine residues, resulting in the formation of intra- and inter-
molecular, covalent ε-(γ-glutamyl)lysine isopeptide bonds
[28]. The involvement of TG2, and also transglutaminase
4 (TG4), another member of TGs that is uniquely distrib-
uted in the prostate gland, has been reported in BPH and
PCa [29–34].
This review will summarize available literature data on
biomarkers of prostate disorders and discuss the role of TG
isoforms as potentially novel diagnostic biomarkers of pros-
tate inﬂammation-related diseases.
2. Current Biomarkers of Prostate Disorders
The ﬁrst biomarker of prostatitis condition was the white
blood cell (WBC) count in prostatic secretion, but then, it
was discarded due to its poor sensitivity [35]. The assessment
of serum levels of prostate speciﬁc antigen (PSA), a member
of the kallikrein gene family, is still carried out for PCa
screening, even though the classiﬁcation of PSA as a PCa bio-
marker has become increasingly controversial due to the lack
of speciﬁcity [36]. Suspicious digital rectal examination
and/or a serumPSA level ≥ 4 0 ng/mL, usually considered as
criteria to prompt further evaluation for PCa [37], has been
the subject of increasingly false positives and overdiagnosis.
For instance, the increase of serum PSA levels has also been
correlated with the aggressiveness of histological inﬂamma-
tion [38]. The low speciﬁcity of this test may be due to the
presence of diﬀerent PSA isoforms, since alternative splicing
and alternative polyadenylation lead to the formation of at
least 15 PSA transcripts, encoding for at least eight diﬀerent
proteins [39]. An investigation about the changes of these
spliced variants in PCa is required for more speciﬁc PSA
screening tests. Notably, several alternatively spliced iso-
forms of other kallikreins (KLK2, KLK3, KLK11, and
KLK15) have been shown to be upregulated in PCa [40].
Chronic inﬂammation has been associated with the
severity of lower urinary tract symptoms (LUTS), higher
International Prostate Symptom Score (IPSS), and higher
prostate volume if compared to prostate in normal condi-
tions [41, 42]. Even though less invasive methods are used
to assess the risk of developing prostatic chronic inﬂamma-
tion, such as detection of circulating biomarkers or imaging,
the unique instrument to make a diagnosis of CP remains the
histological exam [6, 43]. In prostate biopsies, the Chronic
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Prostatitis Symptom Index (CPSI) is utilised to highlight
prostatitis-like symptoms, such as pain and burning sensa-
tion, dribbling and hesitant urination, urgency, or painful
ejaculations. In fact, the total CPSI score is signiﬁcantly asso-
ciated with chronic inﬂammation. Moreover, patients with
CP/CPPS are evaluated with UPOINT (urinary, psychoso-
cial, organ-speciﬁc, infection, neurogenic, and tenderness)
categorization [44].
A further diagnostic feature is the presence of prostatic
calciﬁcations, which increase progressively with aging, and
the incidence of which has signiﬁcantly been associated with
greater inﬂammation and protracted symptoms in patients
with CPPS [45–47].
One of the most reliable prostatic inﬂammation markers
is the level of IL-8 in seminal plasma [48, 49], even in com-
parison with other cytokines [35, 50]. Another experimental
marker of prostatic inﬂammation is the urinary level of
inducible T-cell costimulator (ICOS) protein involved in cell
signaling, immune response, and cell proliferation, that has
been signiﬁcantly associated with maximum uroﬂowmetry
and postvoid residual urine volume [41]. Furthermore, the
involvement of monocyte chemotactic protein-1 (MCP-1)
has been hypothesized in the pathogenesis of CP and BPH,
as its increase in prostatic secretions is associated with pros-
tate volume enlargement and the expression of the macro-
phage marker CD-68 [51, 52].
CP has also been associated with autoimmune responses
against prostate antigens, including prostatic acid phospha-
tase (PAP), prostate steroid-binding protein (PSBP), PSA,
and other antigens in prostate homogenates and seminal
plasma [53–55].
PCa may present with both aggressive and indolent
forms. Given that low-grade prostate cancer is clinically
insigniﬁcant and usually not associated with metastatic dis-
semination, a common practice for the management of
patients with “low risk” or “favorable risk” is active surveil-
lance. This practice is appropriate for men having PSA levels
lower than 10ng/mL and involves the periodic monitoring of
patients through serial PSA testing, digital rectal exam, and
biopsy sampling [56].
The hardest challenges in the clinical practice are the
right selection of patients eligible for biopsy intervention,
the diﬀerentiation of indolent tumors from those with an
unfavorable prognosis, and the early recognition of higher-
risk disease in patients initially diagnosed with low-risk dis-
ease and monitored by active surveillance. Current diagnos-
tic biomarkers of PCa include blood-based tests, such as
ProstateHealth Index® and 4K score®, other than PSA; urine
sample-based tests, i.e., prostate cancer antigen 3 (PCA3),
SelectMDx®, and ExoDx Prostate IntelliScore®; and tissue-
based tests (ConﬁrmMDx®, Oncotype®, Prolaris®, and Deci-
pher®) following biopsy, transurethral resection, or radical
prostatectomy [27].
3. Role of Transglutaminase 4 in
Prostate Disorders
Transglutaminase 4 (TG4) was discovered in the early 1990s
from a human prostate cDNA library [57]. Its physiological
role has ﬁrstly been deﬁned in rodents as a regulator of cop-
ulatory plug formation [58], which is relevant for the fertili-
zation, as it allows the seminal ﬂuid to be kept in the vagina
[59]. Via the incorporation of seminal proteins, such as uter-
oglobin, semenogelins, or polyamines, into sperm cell sur-
faces, TG4 suppresses sperm antigenicity in the female
genital tract [60–62]. The typical TG substrates, polyamines,
in particular putrescine, spermidine, and spermine, are
secreted by the prostate gland and released in the seminal
ﬂuid. In mice and humans, seminal plasma is rich in spermi-
dine and spermine of prostatic origin which may regulate at
the urethra level the seminal clot formation during the ejacu-
latory process [58]. Seminal vesicles, thus even in secretions,
have demonstrated intermediate TG activity and low poly-
amine amount. Notably, the level of protein-bound poly-
amines in ventral and anterior prostate suggests a higher
extracellular activity of prostatic TG and polyamines. Fur-
thermore, Km values of rat prostate TG for all the poly-
amines conﬁrm the regulatory role of polyamines in the
formation of the seminal clot [63]. Interestingly, the presence
of autoantibodies against TG4 in association with human
male infertility has recently been demonstrated, suggesting
that TG4 plays a key role in the fertilization competence of
spermatozoa [64, 65].
The role of TG4 in humans is still not well characterized.
Human TG4 is a secretory protein having an expression pat-
tern restricted to the prostate, where it has been found in
luminal epithelial cells. TG4 is released in the seminal ﬂuid
and responds to androgen stimulation [66, 67]. In this
regard, evidence has been provided that the retinoic acid
receptor gamma (RAR-G) plays a major role in the regula-
tion of TGM4 and that the presence of the androgen receptor
(AR), but not its transcriptional transactivation activity, is
critical for TGM4 transcription [68].
It has been reported that some human prostate cancer
cell lines lack TG4 expression [66], even if a basal transcrip-
tional activity of the promoter was observed [69]. Results
from an analysis of TG4 transcripts in metastatic prostate
cancer specimens indicate that TG4 expression was reduced
in most of them [70]. The downregulation of TG4 expression
in prostate cancer was conﬁrmed by histological analyses of
its distribution within sections from tumor-containing pros-
tatectomy specimens and needle biopsies. The staining was
restricted to luminal epithelial cells and not detected in basal
epithelial or stromal cells. Moreover, TG4 staining was
detected in high-grade prostatic intraepithelial neoplasia
specimens but not in prostate carcinoma cells [67].
Other data have shown that TG4 knockdown is corre-
lated with a lowered invasive ability of prostatic cancer cells
[71]. TG4 expression showed a relatively wide proﬁle in dif-
ferent prostate cancer cell lines and was strongly induced in
the low invasive CA-HPV-10 prostate cancer cell line [71].
Thus, TG4 can be involved with the invasiveness of prostate
cancer cells. A similar result was reported by Jiang and
coworkers showing TGM4 overexpression in a human pros-
tate tumor compared to normal tissue and a higher expres-
sion in high-Gleason score tumors [31].
In a mouse prostate cancer model generated by deletion
of the prostate epithelium-speciﬁc tumor suppressor PTEN,
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TGM4 was rapidly downregulated and the dediﬀerentiation
of the prostatic epithelium was quicker than in organ-
conﬁned human prostate cancers [72]. Other studies have
revealed that TG4 overexpression in prostatic cells increases
the adhesion of tumor cells to endothelial cells and decreases
the barrier function of the latter. Moreover, TG4 sensitizes
prostate cells to hepatocyte growth factor (HGF) [73].
These contradictory results may be explained taking into
account that diﬀerent studies may have addressed their
eﬀorts in the search for the classical TG4 form. However,
proteins obtained by an alternative splicing mechanism
acquire, in part, diﬀerent structural and functional features
compared to the original proteins [74]. These modiﬁcations
are likely responsible for the failure of RT-PCR,Western blot,
and immunohistochemical techniques aimed at detecting the
classical TG4 form. Indeed, Cho and coworkers found four
mRNA variants (L, M1, M2, and S) in the prostatic tissue
of patients aﬀected by BPH and PCa [32]. TG4-M1 and
TG4-M2 have diﬀerent splicing sites but not nucleotide size.
Moreover, TG4-L, TG4-M1, and TG4-M2 have correct open
reading frames, whereas TG4-S has a truncated reading
frame (Figure 1(a)); however, the role of alternative splicing
variants in prostate tissue is not well known.
Notably, TG4-M and TG4-S were detected in all tested
BPH and PCa prostate tissues, while TG4-L was found in
56% of BPH and only in 15% of PCa. These ﬁndings suggest
that changes in alternative splicing correlate with the devel-
opment of PCa. However, TG4-L expression did not corre-
late with PSA serum levels, prostate volumes, or PSA
densities [32]. Interestingly, although TG4 expressed in HeLa
cells has been found as a secreted protein, TG4-L has not
been detected in the supernatant of cell cultures [32].
The diﬀerent cellular localizations suggest a diﬀerent role
for the spliced variants since they likely use diﬀerent protein
substrates, raising the idea that TG4 splicing variants may be
exploited as diagnostic and/or therapeutic targets, as seen
before for other genes in several cancers [75].
TGM4 expression levels were lower in moderately or
poorly diﬀerentiated carcinoma compared with normal tis-
sue [76]. Western blot analysis together with immunohisto-
chemical analysis demonstrated TGM4 downregulation in
prostate cancer [77]. Then, the comparison of protein
markers in prostatic secretions of men having organ-
conﬁned tumors or extracapsular tumors showed diﬀerential
expression of TG4, PSA, ANXA3, and matrix metallopro-
teinases (MMP7 and 9) between the two groups [78].
TG4 resulted also to be involved in cancer disease pro-
gression via promotion of epithelial-mesenchymal transition
(EMT). In fact, in prostate epithelia-derived cancer cells, loss
of E-cadherin, acquisition of N-cadherin, and cell migration
have been highlighted [79].
4. Role of Transglutaminase 2 in
Prostate Disorders
TG2 is a multifunction protein, since other than acting as a
transamidating enzyme, it also displays GTPase, protein
disulﬁde isomerase, kinase, cell adhesion, and scaﬀolding
activities [80].
The function of TG2 in prostate is not fully under-
stood yet. Unlike the prostate-speciﬁc TG4, TG2 is ubiqui-
tous in prostatic tissue and is predominantly present in
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Figure 1: TG4 and TG2 alternative splicing. (a) Alternative splicing in TG4 transcript occurs at the N-terminal domain, leading to the
formation of three variants. The asterisks indicate the exon interested by the splicing mechanism for each variant. (b) The sequence
corresponding to the catalytic core or to the β-barrel domains of TG2 is involved in the splicing events. The intron retention mechanism
that leads to the formation of TG2_v2 aﬀects the exon 10. Shown here is the GTP/GDP binding site that involves also few amino acids
(aa) in the exon 4 (arrow). In yellow is the conserved sequence of the catalytic core, including the cysteine (in bold).
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the intracellular compartment [57, 81]. Likely, TG2 is a
pivotal component of cell signaling because it modulates
the activation of the alpha1-adrenergic receptor, which medi-
ates prostatic smooth muscle contraction [82].
Numerous inﬂammatory cytokines and growth factors
stimulate TG2 expression, such as IL-1, IL-6, TNF-α, and
TGF-β [83–85], due to the presence in TGM2 gene promoter
of diﬀerent regulatory sites for inﬂammatory modulators,
NF-κB response element (-1338 bp), IL-6 speciﬁc cis-regula-
tory element (-1190 bp), and TGF-β1 response element
(-868 bp). TG2 overexpression, in turn, has been reported
to constitutively activate and extend NF-κB activation
through IκBα polymerization and degradation (Figure 2), in
chronic inﬂammatory conditions and in cancer cells [86–88].
TG2 protein and mRNA expression have been evaluated
in experimental models of castration-induced prostatic atro-
phy with subsequent testosterone-induced prostatic hyper-
plasia. TG2 protein was strongly expressed and correlated
with apoptosis. TG2 mRNA levels were not aﬀected during
the process of prostate involution but increased early in asso-
ciation with testosterone-induced proliferation [89]. Interest-
ingly, in men treated with ﬁnasteride, a 5 alpha-reductase
inhibitor, to reduce prostate size and ameliorate BPH symp-
toms, prostate involution has been shown to occur through
both atrophy and cell death processes, in which TG2 has been
demonstrated to play a relevant role [90].
Whey-acidic-protein four-disulﬁde core (WFDC) pro-
teins play a major role as regulators of innate immunity,
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Figure 2: Schematic of the alternative NF-κB activation pathway mediated by TG2. Inﬂammatory signals induce TG2 activation and
interaction with the cytosolic inactive NF-κB complex, composed of the transcriptionally active p50 and p65 subunits and the inhibitory
IκBα subunit. TG2 binding to IκBα leads to IκBα polymerization and release from NF-κB complex, followed by degradation of IκBα
aggregates via a proteasome-independent pathway. The active p50/p65 heterodimer complex, associated with TG2, translocates to the
nucleus where it binds to the NF-κB consensus sequence (GGGRNNYYCC) present in the promoter region of several genes involved in
inﬂammation as well as in tumorigenesis.
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antimicrobial function, and inhibition of inﬂammatory pro-
teases at mucosal surfaces. The prostate stromal 20 (ps20),
a protein of the WFDC family, is a potent growth inhibi-
tion factor, which is also able to modulate the wound heal-
ing process and immune response. It has recently been
shown that the posttranslational processing and cleavage
of ps20 are required to generate a functional protein spe-
cies and that TG2 mediates the cross-linking and cathep-
sin L cleavage to form components of a ps20 regulatory
apparatus [91].
Cancer cells have been reported to express elevated levels
of TG2; moreover, TG2 expression is further highly enriched
in cancer-derived stem cells and promotes their survival [92].
However, conﬂicting results have been reported about the
role of TG2 in PCa.
Despite the fact that TG2 was ﬁrst suggested as a marker
of apoptosis during treatment and progression of PCa [29],
likely other mechanisms play a more relevant role in the
prostate. Birckbichler and coworkers suggested that if all epi-
thelial cells in prostate benign samples are immunoreactive
for TG2, it is possible that the TG2 main function is not the
promotion of apoptosis [93]. Interestingly, immunohisto-
chemistry analysis demonstrated that TG2 expression is
decreased in malignant glands as compared with benign or
hyperplastic glands [93]. This study suggested the potential
use of TG2 loss in prostate tissue as a potential biomarker
for diﬀerentiation of PCa from BPH or other inﬂammatory
conditions. Other than for diagnosis, the determination of
TG2 levels could be useful for individual risk assessment
and patient monitoring [93].
On the other hand, a strong interaction between protein
kinase A anchor protein 13 (AKAP13) and TG2 has been
reported in prostate cancer. Since AKAP plays a major role
in protein kinase A and Rho protein-mediated signaling,
the TG2-AKAP13 interaction has been suggested to play a
role in prostate cancer [30].
Advanced prostate cancer is often associated with
reduced androgen receptor (AR) expression leading to
castration-resistant cancer [94]. In the physiological response
to androgens, the AR binds to androgen-response elements
(AREs) to modulate gene transcription. The transcription
factor Oct1 is a context-dependent negative coregulator
of AR. Notably, siRNA knockdown of Oct1 increases the
transcription of TGM2, an endogenous AR target gene.
Therefore, Oct1 may have regulatory functions in prostate
development and cancer progression [95]. Recent studies
demonstrated high TG2 basal levels in advanced prostate
tumor cells showing a reduced AR expression. Notably,
TG2 was shown to negatively regulate the AR level. In partic-
ular, TG2-mediated NF-κB activation is able to induce NF-
κB binding to DNA elements in the AR gene, which in turn
reduces AR gene expression [34].
Recently, an interesting role of TGM2_v2 (according to
rationalized nomenclature [96]) or TG2 short form has been
highlighted in prostate cell lines or specimens. TGM2_v2
mRNA is obtained from an alternative splicing event with
an intron retention mechanism of intron X, and it encodes
for a 548 aa (63 kDa) protein. The loss of a portion of the
C-terminal domain (Figure 1(b)) decreases aﬃnity for GTP,
resulting in the escape from the negative control mediated
by GTP on TG activity when there is a transient Ca2+
increase [97]. Interestingly, it has been reported that canoni-
cal and alternative TG2 isoforms are all expressed in normal
human prostate tissue, even if the relative amount of TGM2
shorter transcript is small compared with a full-length one
(TGM2_v2 10% vs. 90% TGM2_v1). Alternative splicing of
TGM2 occurs diﬀerently in cancer cell lines, and in prostate
cancer cells the alternative splicing of TG2 is a more active
process. Indeed, the average expression levels of TGM2_v2
were found to be higher than that of the long classic tran-
script (TGM2_v1) in a small screening of prostate cancer tis-
sues compared with normal tissues [96].
On the other hand, the diﬀerentiation treatment with
γ-tocopherol of prostate carcinoma PC3 cells induced a
decrease in the progression into the S-phase, which was asso-
ciated with TG2 upregulation and increased activity, signiﬁ-
cant decrease of DNA synthesis, and protein expression of
cyclins D1 and E. TG2 upregulation and activation could be
part of a larger pathway that promotes the attenuation of
prostate cancer malignancy [98].
5. Conclusions
In the last years, evidence has been provided that human TG4
and TG2 are alternatively spliced in prostate tissues and that
alternative splicing processes occur in association with loss of
prostate tissue homeostasis and transition towards patholog-
ical states, i.e., inﬂammatory conditions and cancer. This
issue needs to be carefully addressed and become object of
further investigations aimed at better understanding whether
diﬀerential alternative splicing may represent a signature of
speciﬁc prostate disorders. In fact, results from these investi-
gations would open new diagnostic perspectives, particularly
if TG4 and TG2, and their alternative variants, could be
detected in serum samples from patients.
It is well known that TG4 is released in seminal plasma.
Although the presence of TG4 in serum has not been inves-
tigated, the detection of autoantibodies against TG4 in the
serum of male patients aﬀected by infertility [64] suggests
that TG4 could also move from seminal plasma to serum. If
this was conﬁrmed, the detection of TG4 and its alternatively
spliced forms in the serum of patients with prostate disorders
could be helpful in discriminating between prostate benign
inﬂammatory conditions and malignant conditions. How-
ever, if the TG4 presence was only restricted to seminal
plasma, the assessment of diﬀerent TG4 variants in seminal
plasma could be helpful for diagnostic purposes and repre-
sent an alternative to biopsy intervention.
TG2 is known to be exported outside the cells, and this
event has been reported in inﬂammatory as well as malignant
conditions [80]. However, its presence in the seminal plasma
and serum has not yet been investigated. Given that TG2
autoantibodies are abundantly present in the serum of
patients aﬀected by celiac disease [99], it is not unreasonable
to hypothesize that also TG2, and likely its alternatively
spliced variants, may be present either in serum or in seminal
plasma. The combined detection of TG4 and TG2 alternative
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variants in seminal plasma and serum could be a powerful
tool for diﬀerential diagnosis of prostate disorders.
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